Adult pure red cell aplasia
diseaseOn this page
Also known as acquired PRCAacquired pure red cell aplasiaadult pure red-cell aplasiaidiopathic pure red cell aplasiapure red-cell aplasia of adults
Summary
Adult pure red cell aplasia (MONDO:0020338) is a disease and 3 clinical trials. Top therapeutic interventions include bortezomib and linperlisib. A subtype of pure red-cell aplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult pure red cell aplasia |
| Mondo ID | MONDO:0020338 |
| Orphanet | 98872 |
| ICD-11 | 45753120 |
| NCIT | C70548 |
| SNOMED CT | 765748009 |
| UMLS | C4707560 |
| MedGen | 1647585 |
| GARD | 0010898 |
| Is cancer (heuristic) | no |
Also known as: acquired PRCA · acquired pure red cell aplasia · adult pure red-cell aplasia · idiopathic pure red cell aplasia · pure red-cell aplasia of adults
Disease family
This is a subtype of pure red-cell aplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › pure red-cell aplasia › adult pure red cell aplasia
Related subtypes (1): Diamond-Blackfan anemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06412497 | PHASE2 | RECRUITING | MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. |
| NCT07031115 | PHASE2 | NOT_YET_RECRUITING | Linperlisib in the Treatment of aPRCA |
| NCT04423367 | PHASE2 | COMPLETED | Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BORTEZOMIB | 4 | 1 |
| LINPERLISIB | 2 | 1 |
Related Atlas pages
- Drugs: Bortezomib